Compile Data Set for Download or QSAR
Report error Found 905 Enz. Inhib. hit(s) with Target = 'High affinity nerve growth factor receptor [441-796]'
LigandPNGBDBM226864(US9328096, 557)
Affinity DataIC50: 1.02nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM227148(US9328096, 836)
Affinity DataIC50: 1.04nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226929(US9328096, 617)
Affinity DataIC50: 1.17nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226759(US9328096, 452)
Affinity DataIC50: 1.43nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226847(US9328096, 540)
Affinity DataIC50: 1.51nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136642(US8865698, 59 | US10047097, 59 | US9676783, 59 | U...)
Affinity DataIC50: 1.70nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136646(US8865698, 63 | US10047097, 63 | US9676783, 63 | U...)
Affinity DataIC50: 1.70nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226527(US9328096, 220)
Affinity DataIC50: 1.71nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226611(US9328096, 304)
Affinity DataIC50: 1.71nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226486(US9328096, 179)
Affinity DataIC50: 1.74nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226998(US9328096, 686)
Affinity DataIC50: 1.77nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226353(US9328096, 46)
Affinity DataIC50: 1.81nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226346(US9328096, 39)
Affinity DataIC50: 1.94nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM227052(US9328096, 740)
Affinity DataIC50: 2.02nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226514(US9328096, 207)
Affinity DataIC50: 2.06nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136640(US8865698, 57 | US10047097, 57 | US9676783, 57 | U...)
Affinity DataIC50: 2.20nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226999(US9328096, 687)
Affinity DataIC50: 2.27nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226472(US9328096, 165)
Affinity DataIC50: 2.45nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226881(US9328096, 574)
Affinity DataIC50: 2.46nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226481(US9328096, 174)
Affinity DataIC50: 2.53nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226483(US9328096, 176)
Affinity DataIC50: 2.60nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226992(US9328096, 680)
Affinity DataIC50: 2.65nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226487(US9328096, 180)
Affinity DataIC50: 2.80nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226807(US9328096, 500)
Affinity DataIC50: 2.84nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226729(US9328096, 422)
Affinity DataIC50: 2.96nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226458(US9328096, 151)
Affinity DataIC50: 2.98nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136650(US8865698, 67 | US10047097, 67 | US9676783, 67 | U...)
Affinity DataIC50: 3nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226485(US9328096, 178)
Affinity DataIC50: 3.05nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136638(US8865698, 55 | US10047097, 55 | US9676783, 55 | U...)
Affinity DataIC50: 3.10nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136641(US8865698, 58 | US10047097, 58 | US9676783, 58 | U...)
Affinity DataIC50: 3.10nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226347(US9328096, 40)
Affinity DataIC50: 3.17nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136667(US8865698, 84 | US10047097, 84 | US9676783, 84 | U...)
Affinity DataIC50: 3.20nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226882(US9328096, 575)
Affinity DataIC50: 3.21nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226874(US9328096, 567)
Affinity DataIC50: 3.22nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM227058(US9328096, 746)
Affinity DataIC50: 3.25nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226529(US9328096, 222)
Affinity DataIC50: 3.37nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226445(US9328096, 138)
Affinity DataIC50: 3.41nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226838(US9328096, 531)
Affinity DataIC50: 3.41nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136654(US8865698, 71 | US10047097, 71 | US9676783, 71 | U...)
Affinity DataIC50: 3.5nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226521(US9328096, 214)
Affinity DataIC50: 3.63nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226352(US9328096, 45)
Affinity DataIC50: 3.92nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136644(US8865698, 61 | US10047097, 61 | US9676783, 61 | U...)
Affinity DataIC50: 4nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136645(US8865698, 62 | US10047097, 62 | US9676783, 62 | U...)
Affinity DataIC50: 4nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136651(US8865698, 68 | US10047097, 68 | US9676783, 68 | U...)
Affinity DataIC50: 4nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226865(US9328096, 558)
Affinity DataIC50: 4.02nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226477(US9328096, 170)
Affinity DataIC50: 4.03nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136624(US8865698, 41 | US10047097, 41 | US9676783, 41 | U...)
Affinity DataIC50: 4.10nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM226853(US9328096, 546)
Affinity DataIC50: 4.14nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136635(US8865698, 52 | US10047097, 52 | US9676783, 52 | U...)
Affinity DataIC50: 4.20nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM136643(US8865698, 60 | US10047097, 60 | US9676783, 60 | U...)
Affinity DataIC50: 4.20nMpH: 7.5Assay Description:Immulon 4HBX 384-well microtiter plates (Thermo part #8755) were coated with a 0.025 mg/mL solution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Vari...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 905 total ) | Next | Last >>
Jump to: